Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monistat 3 leads OTC vaginal yeast infection market with sales of $64.4 mil. -- IRI.

This article was originally published in The Tan Sheet

Executive Summary

McNEIL MONISTAT 3 LEADS VAGINAL YEAST INFECTION MARKET with sales in food, drug and mass market channels of $64.4 mil., up 4.5% in the 52 weeks ended May 24, according to data from Chicago-based Information Resources, Inc. Monistat 7 had higher unit sales than the three-day product -- 5.3 mil. units -- but lower dollar sales ($56.7 mil.), reflecting the seven-day product's lower retail price ($9-$12 versus $13-$16). Monistat 7's dollar sales were down 10.1% from the comparable period the year before, and unit sales fell 5.2%. Both products contain 2% miconazole.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel